Clinical trials: Androgens
Prostate Neoplasms
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
- Trial name
- NCT00544440
- Testing
- Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Janssen Research & Development, LLC
HER2 Amplified, Advanced Breast Cancer
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
The purpose of this study was to evaluate the efficacy of enzalutamide with trastuzumab in patients with HER2+ AR+ metastatic or locally advanced breast cancer.
- Conditions
- HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
- Trial name
- NCT02091960
- Testing
- Enzalutamide, Trastuzumab
- Where
- 39 sites in United States, Belgium and 4 more
- Volunteers
- 103 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Breast Cancer
FDHT PET and Bicalutamide in Metastatic Breast Cancer
Rationale: The purpose is to evaluate whether non-invasive in vivo imaging of androgen receptor (AR) presence in metastatic breast cancer patients by means of 18F-fluoro-dihydrotestosterone positron emission tomography (FDHT-PET)…
- Trial name
- NCT02697032
- Testing
- Bicalutamide, FDHT PET
- Where
- Netherlands
- Volunteers
- 22 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
The purpose of this study is to determine if patients initiating androgen deprivation therapy (ADT) for prostate cancer can be transitioned from degarelix acetate to leuprolide acetate after an initial three-month period without…
- Trial name
- NCT01344564
- Testing
- Degarelix acetate, Leuprolide acetate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Urology of Virginia
Prostate Cancer, Adenocarcinoma of the Prostate
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
MAGIC-8 is a two-arm, multicenter, phase 1b/2 study to assess the efficacy of immunotherapy with either Nivolumab (anti-PD-1) or Nivolumab plus BMS-986253 combined with ADT using Degarelix (LHRH antagonist) for men with…
- Trial name
- NCT03689699
- Testing
- Nivolumab, Degarelix, BMS-986253
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Mark Stein
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00096499
- Testing
- ispinesib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).
- Trial name
- NCT02368691
- Testing
- GTx-024
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- GTx
Polycystic Ovary Syndrome
DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) affects 10% of all women and usually presents with irregular menstrual periods and difficulties conceiving.
- Trial name
- DAISy-PCOS (NCT03911297)
- Testing
- Women with polycystic ovary syndrome
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
RATIONALE: Drugs used in chemotherapy, such as docetaxel and estramustine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083005
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Prostate CA
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06861192
- Testing
- Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy, radical prostatectomy
- Where
- China
- Volunteers
- 83 people
- Sponsor
- baotai Liang
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well finite androgen ablation with or without abiraterone acetate and prednisone work in treating patients with prostate cancer that has come back.
- Trial name
- NCT01786265
- Testing
- Abiraterone Acetate, Bicalutamide, Degarelix
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- M.D. Anderson Cancer Center
Hypogonadism, Male, Physical Activity
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
This study examines the effect of 12-week strength training program with and without testosterone replacement therapy (TRT) on body composition, physical function, selected biochemical markers of metabolic health, molecular…
- Conditions
- Hypogonadism, Male, Physical Activity, Testosterone Deficiency
- Trial name
- NCT03282682
- Testing
- Strength training
- Where
- Slovakia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Comenius University
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
- Trial name
- NCT04126070
- Testing
- Androgen Deprivation Therapy, Nivolumab, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Xiao X. Wei, MD
Prostate Cancer
Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to see if Premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as Premarin may work.
- Trial name
- NCT00134654
- Testing
- Premarin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dana-Farber Cancer Institute
Salivary Gland Carcinoma
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not…
- Trial name
- NCT03942653
- Testing
- Goserelin Acetate, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Manish Patel
Prostatic Neoplasms
Taxotere Prostate Cancer New Indication Registration Trial in China
To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.
- Trial name
- NCT00436839
- Testing
- Docetaxel, Mitoxantrone, Prednisone
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sanofi
Prostate Cancer
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer.
- Trial name
- NCT00780975
- Testing
- Aplidin (plitidepsin)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- PharmaMar
Prostate Cancer
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40Gy/5 fractions/29 days) for the treatment of high risk prostate cancer currently being managed with primary androgen…
- Trial name
- pHART8 (NCT01505075)
- Testing
- Hypofractionated radiation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured…
- Trial name
- VERACITY (NCT04844749)
- Testing
- VERU-111, Enzalutamide, Abiraterone
- Where
- 40 sites in United States
- Volunteers
- 105 people
- Sponsor
- Veru Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.